Scientists Are Expected To Confirm That Ranidine Causes Gastrointestinal Cancer With Slam Dunk Testimony
Studies link ranitidine with becoming NDMA and causing stomach and other forms of cancer
Thursday, June 9, 2022 - Thousands of heartburn medicine cancer victims await the results of hearings scheduled to take place this September where experts from both sides of the case will present scientific testimony. Hearings have been scheduled by Judge Robin Rosenberg presiding over the multidistrict litigation. Both plaintiffs' attorneys and defendants are presenting their scientific evidence and also their objections to the evidence that is counter to their position. The question that is being asked today is whether or not ranitidine, the main ingredient in Zantac heartburn and acid reflux medicine, can cause one or more of several specific types of cancer. Only breast, bladder, colorectal/intestinal, esophageal, gastric, kidney, liver, lung, pancreatic, and prostate cancer will be considered in the hearings. Lawyers are not taking cases involving prostate, colon, lung, kidney, or breast cancers as they are not supported by the MDL rulings. The purpose of the scientific hearings is to select only a couple of experts from both sides to give testimony during the bellwether trials to be held next year. The trial results will go a long way towards determining if Sanofi, the maker of Zantac will offer a monetary settlement or if thousands of cases will be returned to the states where they originated to be tried one by one. If you or a loved one have taken Zantac regularly for more than one year you may have the early stages of one of the types of cancer listed above. Zantac cancer lawyers are advising their clients to seek Zantac cancer testing if they are feeling sick or experiencing weakness or unexplainable loss of appetite or lethargy, common signs that something is wrong. Nausea and stomach bloating are also signs of cancer.
Experts agree that ranitidine is an unstable molecule that degrades into N-nitrosodimethylamine (NDMA) a deadly carcinogen when it is exposed to higher than normal room temperatures. There is also the possibility that it degrades due to human consumption based on the temperature and acidic conditions of the stomach. Scientists that have studied the relationship between ranitidine degrading into NDMA and causing gastrointestinal cancer have concluded that there is a direct causal relationship. Writing for the National Institute of Health Zantac cancer researchers told readers: "The results of the current study provided direct support for the assertion that NDMA contaminated ranitidine is associated with the occurrence of gastrointestinal cancer. This assertion was bolstered by an abundance of evidence demonstrating that NDMA exposure is associated with an increased risk of cancer in humans as well as animals." Zantac was once the world's leading brand of heartburn and acid reflux medicine and was being used by about 15 million Americans regularly when it was recalled in 2020. Online drug testing lab Valisure Inc., tested ranitidine and found levels of carcinogenic NDMA orders of magnitude greater than the 96 nanograms per capsule per day limit set by the FDA.
More Recent Heartburn MedicineLawsuit News:
- Zantac Cancer Trials Are In Discovery To Begin In October 2022 | 7/19/2022
- Zantac Cancer Lawsuits Could Hinge On The Validity of Ranitidine Testing Methods | 7/11/2022
- Zantac Cancer Bellwether Trials In California Could Set The Stage For A Global Settlement Offer | 7/5/2022
- The FDA Recommended Protein Pump Inhibitor Drugs Like Prilosec And Nexium That May Damage Health More Than Zantac | 6/23/2022
- Truck Drivers, Firefighters, and Police Officers May Have Taken More Zantac Than People In Other Occupations | 6/20/2022
Lawyers for Zantac Heartburn Medicine Lawsuits
OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.